Serplus Technology, LLC

Belmont, CA

UEI
MYYCFJYSL4A5
CAGE
65TS6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
111 Poletti Way #9, Belmont, CA 94002, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
PA-21-259, sbir, phase i, serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza R43IP001227 Office of Financial Resources (CDC) $519,226
Enhanced pancreatic islet cell engraftment by treatment with serpin B1 R41DK127818 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $738,843
Regulation of autoimmune type 1 diabetes by serpins B1 and A1 (alpha 1-antitrypsin) R41DK115326 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $212,445
Amelioration of rhinovirus induced asthma exacerbations by serpin B1 R41AI141068 National Institute of Allergy and Infectious Diseases (NIH) $221,645

Similar vendors

Vendor Location Primary NAICS
Amid Biosciences LLC UEI C8WKD184KBY5 Santa Clara, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Xylome Corp UEI K7RTL7E9JLE6 Madison, WI 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

SBA capabilities narrative

From the vendor's SBA profile

Recombinant protein production in yeast

Protein purification and analytical services

Fermentation development services

Drug development consulting

Quick answers

Is Serplus Technology, LLC registered in SAM.gov?

Yes. Serplus Technology, LLC's SAM.gov registration is active through July 23, 2027.

What is Serplus Technology, LLC's most recent federal award?

Serplus Technology, LLC's most recent federal grant award is PA-21-259, sbir, phase i, serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza (R43IP001227), from Office of Financial Resources (CDC), on September 30, 2023.

On GovTribe

See Serplus Technology, LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login